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Pharmacokinetics of oxfendazole nanosuspension in sheep

Yuzhu Sun1 Xiaofang Wang3 Aoxue Zhang1 Bao Zhang1 Liwei Shao3 Yue Liu3
Haiting Wang4 Wanhe Luo1 Dongmei Chen1,2* Shuyu Xie1*

Abstract
The pharmacokinetics of our previous prepared oxfendazole nanosuspension was studied in sheep to understand
its enhancement of bioavailability. Ten sheep were randomly divided into two groups, each of which received a singledose (5mg/kg) oral oxfendazole nanosuspension and oxfendazole granules. After intragastric administration,
oxfendazole rapidly reached peak concentrations of 11.25 μg/mL and 5.50 µg/mL at 5.6 h and 6.6 h in the
nanosuspension group and granules group and the concentrations gradually reduced to below the detection limit at 96
h and 72h, respectively. The main pharmacokinetic parameters of oxfendazole after administration to the sheep: The
Tmax, Cmax, AUClast, MRTlast, T1/2 and Ke of in nanosuspension were 5.6 h, 11.26 µg/mL, 179.22 µg*h/mL, 17.82 h, 87.22
h and 0.012 1/h, respectively, while the these main pharmacokinetic parameters in the OFZ granules group were 6.6 h,
5.50 µg/mL, 105.28 µg*h/mL, 16.55 h, 35.04 h, and 0.020 1/h, respectively. Compared with the granules group, the C max
and AUClast of the nanosuspension group were increased by 2.05 and 1.70 times, respectively, and the Cmax and AUClast
of the total active compound in the nanosuspension group were increased by 1.85 times and 1.71 times, respectively.
These results suggest that the oxfendazole suspension might be an effective and promising formulation for use in sheep.
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Introduction

Materials and Methods

Oxfendazole (OFZ), whose chemical structure is
Methyl 5-(phenylsulfinyl)-benzimidazol-2-carbamate,
is a derivative of fenbendazole. It is a new broadspectrum, high-efficiency and low-toxicity insect
repellent drug. OFZ is metabolized to fenbendazole
(FBZ) and fenbendazole sulfone (FBZSO) in ruminants
but its main repellent effect is still derived from itself.
OFZ, FBZ and FBZSO can be detected in serum after
the use of OFZ, and OFZ is the main component
(Lanusse et al., 1995). It has a good repellent effect on
lung nematodes, abdominal worms and aphids (Barr et
al., 1993; Blanton et al., 1998; Davies and Schwalbach,
2000; Gavidia et al., 2009, 2010). In addition, it has a
good deworming egg effect (Duwel et al., 1975). Studies
have reported that OFZ exhibits a more efficient
deworming effect than other similar deworming drugs
(Bauer, 1990; Ploeger and Everts, 2018). It is safe and
well tolerated in animals and humans (Gonzales et al.,
1996; Gonzalez et al., 1997; An et al., 2019) and it is
gradually used to prevent and treat gastrointestinal
parasitic diseases and various helminthiasis. However,
it should be noted that OFZ is a biopharmaceutical
classification system (BCS) class II drug (a drug with
low solubility and high permeability) (An et al., 2019)
with concentration-dependence; a higher oral
absorption concentration is required to achieve good
deworming effects in vivo. However, the existing
formulations have not solved the solubility problem of
OFZ. Therefore, the challenge of solubility and oral
absorption of OFZ should be urgently resolved.
In order to solve the problem of poor oral
absorption, our group proposed a method for
preparing OFZ nanosuspension by adding surfactant.
The OFZ nanosuspension was prepared by acid-base
neutralization combined with ultrasonic dispersion. 5
g of OFZ was dissolved in 20 mL saturated malic acid
solution at 75℃ and stirred with a magnetic stirrer. A
2.5 mol/L NaOH of the same molar mass solution
containing 1.5g polyoxyethylene ether hydrogenated
castor oil (HEL-40) at 4℃ was quickly poured into an
acidic aqueous solution containing OFZ under stirring
at 500 r/min; after that the drug had complete
precipitation. The recrystallized OFZ was sonicated for
6 mins using 6 mm microprobes with 91% amplitude
(VCX 130 Vibra-CellTM, Sonics & Materials, Inc.,
Newtown, CT, USA) to obtain the uniform particle
diameter. The preparation method was simple and
could meet the requirements of clinical application. In
previous experiments, the equilibrium solubility of
nanocrystals in different solvents was significantly
improved by 2.02-109.99-fold compared to OFZ
powder. The in vitro release speed was improved
significantly and the pharmacokinetics showed that
the relative bioavailability of the OFZ nanosuspension
was 265.61% compared to the OFZ granules in rats.
This indicates that it is a very well worth developing
the preparation.
In addition, there are no reports on the
pharmacokinetics of OFZ nano preparations currently.
The HPLC method was used to determine the
concentration of OFZ and its metabolites in the plasma
of sheep. This research can provide the basis for the
clinical application of the preparation.

OFZ granule (Specifications 10%) was purchased
from Jiangxi Tebang Biopharmaceutical Co., Ltd.
(Jiangxi, China). OFZ nanosuspension (specification
7.5%) was obtained from our laboratory. Methanol,
acetonitrile,
and
ammonium
acetate
were
commercially available from Sinopharm Chemical
Reagent Co., Ltd (Shanghai, China). Ultrapure water
for all experiments was obtained with a Microporous
Purification® Purified Water System (Milli-Q Ltd.,
France). All other chemicals and reagents used in this
experiment were of analytical grade. The ten healthy
small-tailed Han rams had an average weight of
38.6±1.2 kg. The experimental sheep were fed 3 times a
day and drank freely at a room temperature of -3 to
10℃. The experiment was carried out according to the
"Guidelines of the Care and Use of Laboratory
Animals" of Huazhong Agricultural University and
approved by the Ethics Committee of Huazhong
Agricultural University.
Animal study: Ten sheep of uniform weight were
selected and randomly divided into two groups; the
first group was the OFZ nanosuspension group and the
second group was the OFZ granules group. They were
free to drink and eat. The feed was a full-price diet
without antibacterial drugs. After clinical observation
for 7 days, single-dose gastric administration at
5mg/kg and they could only drink freely within 12
hours before the test and within 4 hours after the test.
After administration, 5 mL of intravenous blood was
collected from sheep at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72,
96, 120 and 144 h. The collected blood samples were
placed in a centrifuge tube containing sodium heparin,
mixed, centrifuged at 8000 r/min for 10 minutes and
the upper plasma was placed on standby at -20℃.
Plasma sample pretreatment: For the analysis of drug
concentration in plasma, a 1 mL plasma sample was
added to a 10 mL centrifuge tube and deproteinized
with 1 mL acetonitrile. Furthermore, 2 mL of ethyl
acetate and 0.1 mL of 0.1 mol/mL aqueous ammonia
solution were added under vorticity for 3 mins to be
completely mixed. The mixture was centrifuged at
8000 r/min at 4°C for 10 minutes and the supernatant
was transferred to another 10 mL centrifuge tube. 2 mL
of ethyl acetate were added to the precipitate to repeat
the extraction. Extracts was dried with nitrogen at 50℃
and resoluble with 0.2 mL of mobile phaseand
analyzed by HPLC after filtration through a 0.22 μm
cellulose membrane.
HPLC assay: The detection of OFZ, FBZ and FBZSO in
all samples in this test was carried out according to the
HPLC methods reported in our previous work(Chen et
al., 2010). The chromatographic conditions were as
follows: Agilent (1100 series) and Ecilpse XDB-C18 (4.6
ID×250 mm, Agilent, USA); detection wavelength, 292
nm; flow rate, 1 mL/min; column temperature, 25℃;
and injection volume, 50 μL, A gradient elution mode
of the mobile phase (A: 0.02 M ammonium acetate, B:
acetylene) was set up to separate OFZ and its major
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metabolites. The gradient was set as follows: 0 minutes,
85% A; 10 minutes, 50% A; 20 minutes, 50% A.
Statistical analysis: Non-compartmental analysis was
accomplished using WinNonlin version 5.0 for
pharmacokinetic analysis. The plasma concentrationtime curve area (AUC), drug peak concentration (Cmax),
time reached the maximum concentration (Tmax),
elimination half-life (T1/2) and average retention time
(MRT) were calculated. The statistical significance of
differences in pharmacokinetic parameters between
the granules and the nanosuspension group was
analysed by Anova Analysis using SPSS 17.0 (SPSS Co.
USA). Significant differences and extremely significant
differences were determined as p values of 0.05 and
0.01, respectively. The data was analysed in triplicate.

Results
HPLC method: The drug and its metabolites had a
good linear relationship in the concentration range of
0.05-15 µg/mL, and the correlation coefficients were all
above 0.999. The LOD and LOQ of the three
compounds were 0.05 μg/mL and 0.5 μg/mL,
respectively. The average recoveries of OFZ, FBZ and
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FBZSO in plasma were 89%-110% and the intra- and
inter-assay coefficients of variation were less than 5%
respectively. This established that the method was
suitable for detecting OFZ and its active metabolites in
plasma.
Pharmacokinetics: All sheep tolerated the oral
administration of OFZ granules and the OFZ
nanosuspension well without any abnormal
phenomena. The plasma concentration-time curves of
OFZ granules and the OFZ nanosuspension are shown
in figure 1-3. After oral administration, the
concentrations of OFZ in blood reached maximum
concentrations of 5.50 µg/mL and 11.26 µg/mL at 6.60
h and 5.60 h in granules group and nanosuspension
group, respectively, and gradually decreased to the
LOD at 72 h and 96 h. The metabolites FBZ reached
maximum concentrations of 1.34 µg/mL and 1.45
µg/mL at 10.60 h and 3.69 h in granules group and
nanosuspension group, respectively, and slowly fell to
the LOD at 72 and 96 h. Another metabolite, FBZSO,
reached maximum concentrations of 2.20µg/mL and
4.12 µg/mL at 17.60h and 18.40 h in granules group
and nanosuspension group, respectively, and both fell
to the LOD at 144 h.

Figure 1

The plasma concentrations versus time curves of OFZ after oral administration at a dose rate of 5 mg/kg.B. W to sheep.

Figure 2

The plasma concentrations versus time curves of FBZ after oral administration at a dose rate of 5 mg/kg.B. W to sheep.
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Figure 3

The plasma concentrations versus time curves of FBZSO after oral administration at a dose rate of 5 mg/kg.B. W to sheep.

The area under the concentration time curve of
FBZSO (AUClast) and the elimination half-life (T1/2) in
the OFZ nanosuspension groups were 170.8412.76
h*ng/mL and 37.774.42 h, while these parameters for
the OFZ granules were 107.3515.50 h*ng/mL and
46.2218.07 h, respectively. Compared to OFZ
Table 1

Table 2

Table 3

granules, the AUClast was increased by 1.59 times,
respectively. Comparison of the average MRTlast of the
three
active
ingredients
shows
that
the
nanosuspension group was 17.82 h, 21.61 h, and 37.19
h, respectively. There was no significant difference
between the two groups (Table1-3).

Comparison of the pharmacokinetic parameters of OFZ after oral administration at a dose rate of 5 mg/kg.B. W to sheep.
Parameters

OFZ granules

OFZ nanosuspension

ANOVA test (p)

Tmax(h)

6.602.19

5.602.19

0.398

Cmax(µg/ml)

5.500.76

11.264.29

0.034*

AUClast（h*µg/ml）

105.2811.26

179.2274.35

0.043*

MRTlast（h）

16.551.6

17.822.01

0.064

Ke

0.0200.000

0.0120.006

0.016*

T1/2

32.0020.62

41.2023.94

0.533

Comparison of the pharmacokinetic parameters of FBZ after oral administration at a dose rate of 5 mg/kg.B. W to sheep.
Parameters

OFZ granules

OFZ nanosuspension

ANOVA test (p)

Tmax(h)

10.608.17

3.691.66

0.184

Cmax(µg/ml)

1.450.98

1.340.82

0.299

AUClast（h*µg/ml）

27.8212.57

28.858.46

0.964

MRTlast（h）

27.708.06

21.618.10

0.914

Ke

0.0110.003

0.0090.000

0.779

T1/2

30.2512.48

57.3829.01

0.091

Comparison of the pharmacokinetic parameters of FBZSO after oral administration at a dose rate of 5 mg/kg.B. W to
sheep.
Parameters

OFZ granules

OFZ nanosuspension

ANOVA test (p)

Tmax(h)

17.608.76

18.407.80

0.762

Cmax(µg/ml)

2.200.41

4.120.53

0.033*

AUClast（h*µg/ml）

107.3515.50

170.8412.76

0.012*

MRTlast（h）

39.703.16

37.192.63

0.486

Ke

0.0040.002

0.0040.002

0.212

T1/2

46.2218.07

37.774.42

0.340

＊

Statistical significances compared with OFZ granules are p＜0.05

Discussion
The HPLC analysis method of OFZ, FBZ and
FBZSO in sheep plasma established in this study has

certain specificity. The three drugs were completely
separated by the gradient elution of acetonitrile and
ammonium acetate. The retention times were 8.4mins,
16.9mins, and 14.1mins, respectively, and no
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interference peaks appeared near the drug peak. After
determining the analytical method of the mixed drug,
the linearity, precision and stability were verified and
the results met the requirements of the biological
sample analysis method.
Compared with the pharmacokinetic parameters of
OFZ granules in sheep, OFZ nanosuspension
significantly improved bioavailability. The main
reason for the increase in bioavailability may be that
the particle size of the nanosuspension is in the
nanometer range, and the surface area is greatly
increased, which increases the solubility and enhances
the adhesion to the gastrointestinal tract, making it
possible to achieve higher drug locally concentrated,
higher deworming effects may be possible for
gastrointestinal nematodes. With time, the drug is
slowly released from the interstitial space and the
circulation time in the body is prolonged, so the
residence time and absorption of the drug particles in
the gastrointestinal tract are increased and it can
prolong the deworming time in the body. Another
reason may be that the stabilizers selected in the
formulation have good compatibility with tissues and
mucous membranes and the surface charge of the
nanoparticles affects the permeability of small
intestinal epithelial cells, thereby affecting plasma
drug levels (Ban et al., 2020).
In short, the results of this test show that OFZ
nanosuspension is expected to become a more effective
preparation for the treatment of gastrointestinal
nematode disease in ruminants, with great further
development value.
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